Easywell Biomedicals (ROCO:1799) Cyclically Adjusted Revenue per Share: NT$5.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:1799 Easywell Biomedicals Inc ROCO:1799
54 GF Score
Price NT$31.65
GF Value NT$83.08
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Easywell Biomedicals Cyclically Adjusted Revenue per Share?

Easywell Biomedicals ROCO:1799 -1.56% 54 Cyclically Adjusted Revenue per Share is NT$5.23 as of Mar. 2026. GuruFocus rates ROCO:1799 with a GF Score™ of 54/100 and a GF Value™ of NT$83.08 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Easywell Biomedicals's adjusted revenue per share for the three months ended in Mar. 2026 was NT$1.858. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$5.23 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Easywell Biomedicals's average Cyclically Adjusted Revenue Growth Rate was -6.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -6.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Easywell Biomedicals was -0.90% per year. The lowest was -6.90% per year. And the median was -3.85% per year.

As of today (2026-08-07), Easywell Biomedicals's current stock price is NT$31.65. Easywell Biomedicals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$5.23. Easywell Biomedicals's Cyclically Adjusted PS Ratio of today is 6.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Easywell Biomedicals was 36.88. The lowest was 1.58. And the median was 3.88.


Easywell Biomedicals  (ROCO:1799) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Easywell Biomedicals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=31.65/5.23
=6.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Easywell Biomedicals was 36.88. The lowest was 1.58. And the median was 3.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Easywell Biomedicals Cyclically Adjusted Revenue per Share Related Terms


Easywell Biomedicals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Easywell Biomedicals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Easywell Biomedicals Cyclically Adjusted Revenue per Share Chart

Easywell Biomedicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.32 6.21 6.06 5.82 5.01

Easywell Biomedicals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.57 5.22 5.16 5.01 5.23

ROCO:1799 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Easywell Biomedicals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Easywell Biomedicals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Easywell Biomedicals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Easywell Biomedicals's Cyclically Adjusted PS Ratio falls into.


ROCO:1799
54GF Score
Easywell Biomedicals Inc ROCO:1799
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Easywell Biomedicals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Easywell Biomedicals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.858/330.2130*330.2130
=1.858

Current CPI (Mar. 2026) = 330.2130.

Easywell Biomedicals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.507 241.018 2.065
201609 2.837 241.428 3.880
201612 1.875 241.432 2.564
201703 1.713 243.801 2.320
201706 1.827 244.955 2.463
201709 1.653 246.819 2.212
201712 1.041 246.524 1.394
201803 1.318 249.554 1.744
201806 1.192 251.989 1.562
201809 1.367 252.439 1.788
201812 2.124 251.233 2.792
201903 1.136 254.202 1.476
201906 1.397 256.143 1.801
201909 1.032 256.759 1.327
201912 0.993 256.974 1.276
202003 0.874 258.115 1.118
202006 0.741 257.797 0.949
202009 0.357 260.280 0.453
202012 0.881 260.474 1.117
202103 0.726 264.877 0.905
202106 0.460 271.696 0.559
202109 0.363 274.310 0.437
202112 0.321 278.802 0.380
202203 0.303 287.504 0.348
202206 0.305 296.311 0.340
202209 0.371 296.808 0.413
202212 0.578 296.797 0.643
202303 0.320 301.836 0.350
202306 0.618 305.109 0.669
202309 0.603 307.789 0.647
202312 0.828 306.746 0.891
202403 0.626 312.332 0.662
202406 1.011 314.175 1.063
202409 1.456 315.301 1.525
202412 1.262 315.605 1.320
202503 1.215 319.799 1.255
202506 0.871 322.561 0.892
202509 1.453 324.800 1.477
202512 1.296 324.054 1.321
202603 1.858 330.213 1.858

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$5.23 mean?
Easywell Biomedicals (ROCO:1799) has a Cyclically Adjusted Revenue per Share of NT$5.23 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Easywell Biomedicals and its competitors.
Is Easywell Biomedicals' Cyclically Adjusted Revenue per Share too high?
Easywell Biomedicals' current Cyclically Adjusted Revenue per Share is NT$5.23. Overall, Easywell Biomedicals has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Easywell Biomedicals' Cyclically Adjusted Revenue per Share compare to ZTS?
Easywell Biomedicals' Cyclically Adjusted Revenue per Share of NT$5.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Easywell Biomedicals and its competitors. Easywell Biomedicals's current Cyclically Adjusted Revenue per Share is NT$5.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Easywell Biomedicals stock overvalued right now?
Based on GuruFocus' analysis, Easywell Biomedicals (ROCO:1799) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$83.08, compared to a current price of NT$31.65 — trading 61.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$5.23. Easywell Biomedicals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Easywell Biomedicals (ROCO:1799), the current Cyclically Adjusted Revenue per Share is NT$5.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Easywell Biomedicals (ROCO:1799) Overvalued in 2026?

Based on GuruFocus' analysis, Easywell Biomedicals stock appears to be undervalued. The current stock price of NT$31.65 is trading 61.9% below its estimated GF Value™ of NT$83.08. GuruFocus considers Easywell Biomedicals to be Significantly Undervalued.

Key valuation signals for ROCO:1799:

  • Cyclically Adjusted Revenue per Share: NT$5.23
  • GF Value™: NT$83.08 vs. price of NT$31.65 (61.9% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ROCO:1799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Easywell Biomedicals Business Description

Address No.10, Yanfa 2nd Road, Hsinchu Science Park, 1st floor, Hsinchu, TWN, 30076
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients, generic drugs, and new drugs. It focuses on complex generics, new drug delivery platforms, and regenerative medicines, with cGMP. The company's segments include the Drug Development segment and the Other segment. Geographically, the company operates in America, China, and Taiwan regions.
54GF Score

Get the complete analysis for ROCO:1799

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.65
Price
NT$83.08
GF Value